Chemical formula: C₈H₅F₃N₂OS Molecular mass: 234.198 g/mol PubChem compound: 5070
Riluzole is indicated for:
Population group: only adults (18 years old or older)
Riluzole is indicated to extend life or the time to mechanical ventilation for patients with amyotrophic lateral sclerosis (ALS).
Clinical trials have demonstrated that riluzole extends survival for patients with ALS. Survival was defined as patients who were alive, not intubated for mechanical ventilation and tracheotomy-free.
There is no evidence that riluzole exerts a therapeutic effect on motor function, lung function, fasciculations, muscle strength and motor symptoms. Riluzole has not been shown to be effective in the late stages of ALS.
Safety and efficacy of riluzole has only been studied in ALS. Therefore, riluzole should not be used in patients with any other form of motor neurone disease.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Riluzole is contraindicated in the following cases:
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
